Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2002

View Archived Issues

New treatment option for ADHD available in the U.S.

First FDA-approved dual-component lipid modulator reaches market

RBx-7644: a new oxazolidinone presented by Ranbaxy at ICMASKO

Novel macrolides evaluated in vitro and in murine infection models at GSK and Pliva

KRX-101 cleared to enter South African phase II trial in HIV-associated nephropathy

Preclinical data support expanded preclinical program for HRC-102

Inspire reprioritizes its pipeline

MG-98 enters clinical trials in MDS and AML

Pozen's antimigraine product candidate noncarcinogenic in mice

Epimmune reschedules IND filing for lead HIV vaccine candidate

Antiarrhythmics and antidepressants discovered to be fungicidal

Sugen claims compounds that modulate protein kinases and phosphatases

Antibacterial oxazolidinones with potent and broad-spectrum activity

Patent covers new NK1 antagonists designed at Roche

Pyrrolopyrimidine-2,4-dione derivatives that selectively inhibit PDE5 identified

Adamantane-based P2X7 receptor antagonists discovered by AstraZeneca team

Byk Gulden synthesizes dual beta2-adrenoceptor agonist/PDE4 inhibitor compounds

Bicyclic cyclohexylamines with utility in Parkinson's disease described in patent

Compounds useful in hyperproliferative disorders claimed by Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...